Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06800066 · ClinicalTrials.gov registry record · NA
RCT-Consumer Perceptions of Cannabidiol (CBD) Health Claims
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 460
- Enrollment target
NCT06800066 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 460 participants.
The verdict
NCT06800066, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 460 participants
- Enrollment target
Study Summary
Cannabidiol (CBD) cannot be marketed as having therapeutic benefits (without FDA's approval), be false or misleading to consumers, or convey the products are approved or endorsed by the FDA. In addition, CBD cannot be marketed as a food additive or dietary supplement since it is an active ingredient in an approved drug, Epidiolex. Despite this, CBD products have been illicitly advertised to consumers with these claims including unsubstantiated health claims that promote benefits including curing cancer and preventing Alzheimer's disease. These types of claims may be influencing consumers to use CBD. This study aims to examine the impact of CBD advertising with health claims on consumer purchase behavior.
Interventions
- BEHAVIORAL Purchase Behavior - (Non-CBD ads)
- BEHAVIORAL Purchase Behavior - (CBD ads)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2025-01-08 |
| Est. Completion | 2025-08-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06800066
The ClinicalTrials.gov registry entry for NCT06800066 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Purchase Behavior - (Non-CBD ads) is the first listed.
NCT06800066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06800066 about?
NCT06800066 is a clinical study titled "RCT-Consumer Perceptions of Cannabidiol (CBD) Health Claims". Cannabidiol (CBD) cannot be marketed as having therapeutic benefits (without FDA's approval), be false or misleading to consumers, or convey the products are approved or endorsed by the FDA. In addition, CBD cannot be marketed as a food additive or dietary supplement since it is an active ingredient...
What is the current status of trial NCT06800066?
This trial is currently completed. It is a NA study. The enrollment target is 460 participants. The study started on 2025-01-08. Estimated completion is 2025-08-15.
What interventions are being tested in trial NCT06800066?
The interventions under investigation include: Purchase Behavior - (Non-CBD ads) (BEHAVIORAL), Purchase Behavior - (CBD ads) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06800066?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.